Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Brian Liang"'
Autor:
Xiuling Lu, Gaurav N. Joshi, Michael Jay, Andrew L. Salner, Laura Gonzalez-Fajardo, Derek Hargrove, Brian Liang, Sterling Glass, Raana Kashfi-Sadabad
Publikováno v:
J Control Release
The use of intraperitoneal administration of nanoparticles has been reported to facilitate higher concentrations of nanoparticles in metastatic peritoneal tumors. While this strategy is appealing for limiting systemic exposure of nanocarrier delivere
Autor:
Brian Liang, Qianqian Ni, Fuwu Zhang, Gang Niu, Ting Su, Longjiang Zhang, Yijing Liu, Xiaoyuan Chen, Guangming Lu, Guocan Yu, Zhantong Wang, Guizhi Zhu
Publikováno v:
Science Advances
A rationally designed bi-adjuvant nanovaccine enhances neoantigen immunogenicity and enables combination immunotherapy.
Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantige
Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantige
Publikováno v:
Nanomedicine: Nanotechnology, Biology and Medicine. 14:1849-1850
Publikováno v:
Cancer Research. 73:3277-3277
Objectives. Veliparib (ABT), a PARP1/2 inhibitor, has been studied in ovarian adenocarcinoma treatment, particularly in conjunction with platinum therapy, and sensitizes cells to cisplatin (Cis). Pifithrin-α (PFT), a transcriptional inhibitor of p53
Autor:
Qianqian Ni1,2, Fuwu Zhang2, Yijing Liu2, Zhantong Wang2, Guocan Yu2, Brian Liang2, Gang Niu2, Ting Su3,4, Guizhi Zhu3,4 gzhu2@vcu.edu, Guangming Lu1 cjr.luguangming@vip.163.com, Longjiang Zhang1 kevinzhlj@163.com, Xiaoyuan Chen2 shawn.chen@nih.gov
Publikováno v:
Science Advances. 3/18/2020, Vol. 6 Issue 12, p1-12. 12p.